The Carlyle Group made a strategic growth investment and will acquire a majority stake in TriNetX, a global health research network focused on clinical research to bring new therapies . . .
Continue Reading With a Free Trial
Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.
Already a subscriber? Log in.